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Two telephone surveys were conducted during October
3—11 and December 15—17, 2007 targeting people aged
65 and older randomly sampled by the Computer Assisted
Telephone Interview (CATI). Questionnaires were developed
under the theoretical framework of the health belief model.
Among 1,115 effective samples of pre-survey, 512 (45.9%)
were successfully followed.
512 people of post-survey were representative of
pre-survey population because of their comparability of
demographic characteristics. 62.6% (698/1,115) expressed
their willingness to receive vaccination and 61.0% (312/512)
among post-survey samples actually received vaccina-
tion. Important factors inﬂuencing their willingness were
their beneﬁcial belief in vaccination (OR = 19.8, 95%
CI = 10.0—39.2), with obstacles of vaccination (OR = 8.0, 95%
CI = 5.0—12.7), awareness of disease seriousness (OR = 1.9,
95% CI = 1.2—3.0). The relevant factors for actual vac-
cination were living with chronic disease (OR = 2.2, 95%
CI = 1.1—4.1), fear of contracting inﬂuenza (OR = 3.2,
95%CI = 1.8—5.8, fear of health impairment OR = 3.3, 95%
CI = 1.7—6.7, fear of adverse effects of vaccination (OR = 0.2,
95% CI = 0.1—0.3) and unawareness of disease threat
(OR = 0.5, 95% CI = 0.30.9).
The rate of willingness, approximately to the actual
rate of vaccination, and the similar attitude and beliefs
on inﬂuenza vaccination between two survey population
demonstrate the difﬁculty of conducting propaganda for
the elderly. However, target-oriented, focusing relevant fac-
tors and selecting appropriate media channels would be the
solution for the challenge of high vaccination rate of the
elderly.
doi:10.1016/j.ijid.2008.05.363
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Children suffer severe effects of inﬂuenza and play a
major role in disease transmission. Therefore prepandemic
inﬂuenza vaccination of children may be a highly effective
measure to contain the spread of pandemic inﬂuenza and to
reduce its morbidity and mortality.
This pediatric study (107066/NCT00502593) evaluated
the safety of two administrations, 21 days apart, of an
H5N1 split virus inﬂuenza vaccine containing 1.9g HA
(A/Vietnam/1194/2004) adjuvanted with an oil-in-water
emulsion-based Adjuvant System (H5N1/AS group) as com-
pared to immunizations with the non-adjuvanted seasonal
inﬂuenza vaccine FluarixTM (control) marketed by Glax-
oSmithKline. For this partial preliminary analysis, 138
children aged 3—9 years completed the safety evaluation
(H5N1/AS-[3—5y]:N = 51, (H5N1/AS-[6—9y]:N = 51, Control-
[3—5y]:N = 18; Control-[6—9y]:N = 18). Solicited local (SLS)
and general (SGS) symptoms, adverse events (AE) and seri-
ous AE (SAEs) were recorded.
Considering a 50 days follow-up period, injection site
pain was the most frequent SLS in both H5N1/AS and con-
trol groups (30/51 vs. 7/18 for 3-5y children; 44/51 vs. 12/18
for 6-9y children), with grade-3 pain in 2/51 children from
the H5N1/AS-[3—5y] group vs. 0 in the Control-[3—5y] group
and in 5 children from the H5N1/AS-[6—9y] group vs. 0 in
the Control-[6—9y] group. SGS were more frequent in the
H5N1/AS group. Grade-3 SGS were reported in 4/51 chil-
dren in the H5N1/AS-[3—5y] group (2 fever>39.1 ◦C, 2 losses
of appetite, 1 drowsiness) and in 0/18 in the correspond-
ing control group. For the 6-9y group, grade-3 SGS were
reported in 4/51 children in the H5N1/AS (2 headaches, 1
gastrointestinal disorder, 1 myalgia) and in 1/18 in the cor-
responding Control group (1 fever>39.1 ◦C). Most symptoms
lasted 1-2 days with no increase of duration or severity with
the second dose. No distinct pattern of symptomatology was
noted. No SAEs were reported.
In children aged 3—9 years, the candidate H5N1 AS-
adjuvanted vaccine did not raise any safety concerns and
the reactogenicity proﬁle was clinically acceptable.
doi:10.1016/j.ijid.2008.05.364
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Prepandemic H5N1 vaccines should be antigen-sparing,
have acceptable reactogenicity and offer cross-reactive
immunity to non-vaccine strains. Most clinical studies
have evaluated clade 1 strains which infected humans in
2004—2005, while clade 2 strains have infected humans since
2005. We evaluated two H5N1 vaccine candidates made with
a clade 2.1 strain.
The vaccine candidates, produced at 2 sites (Dres-
den [D], Quebec [Q]) by 2 distinct processes, were
made with A/Indonesia/5/2005 (clade 2.1) antigens.
Adults (18—64 years) were vaccinated twice, 21 days
apart, with 3.8g of hemagglutinin (HA) with an oil-in-
water emulsion-based Adjuvant System (AS) or without
(control). 150 subjects received AS-adjuvanted D- or
Q-antigens, while 75 control subjects received a non-
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adjuvanted Q-antigen. At days 0, 21 and 42, sera were
tested for hemagglutination-inhibiting (HI) antibody against
A/Indonesia/5/2005 and A/Vietnam/1194/2004 (Clade 1).
Solicited local and general symptoms, unsolicited adverse
events (AEs) and serious adverse events (SAEs) were
recorded. (110028/NCT00510874).
Although injection site pain was more frequent in the AS-
adjuvanted vaccine groups, redness and swelling occurred
in <5% of subjects. General symptoms (day 0—6) were more
frequent in the AS vaccine groups but fever was uncommon
(≤2%). All AEs decreased after dose 2. Clinical laboratory
values and unsolicited AEs raised no safety concerns. No
vaccine-related SAEs occurred.
After dose 1, A/Indonesia seroconversion rates (SCR)
reached 42.1%—45.7% in the AS vaccine groups (con-
trol:6.7%). After dose 2, SCR and the percent of subjects
with HI titers ≥40 were 96.4%—97.2% in the AS vaccine
groups (control:17.3%). Homologous HI GMT was enhanced
≥44-fold in the pooled AS vaccine group. After 2 doses, SCR
to Clade 1A/Vietnam/1194/04 was 56.4%—62.1% for the AS
vaccine groups.
At an antigen-sparing dose, the AS-adjuvanted
A/Indonesia/05/2005 vaccines were markedly immunogenic
against the vaccine strain and a Clade 1 strain. Reacto-
genicity was increased but acceptable, and no other safety
concerns were identiﬁed.
doi:10.1016/j.ijid.2008.05.365
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Background: The lyophilized formulation of an oral, live
attenuated human rotavirus (RV) vaccine RIX4414 (Rotarix, a
trademark from GlaxoSmithKline) given concomitantly with
routine vaccines, has been shown to be highly immunogenic.
A phase II, randomised, double-blind, placebo-controlled
study (105722/NCT00345956) was conducted in Vietnam to
assess the immunogenicity, reactogenicity and safety of two
doses of RIX4414 oral suspension(liquid formulation) co-
administered in two different schedules with routine EPI
vaccines.
Methods: Healthy 6—10 week old infants(N = 375) were
enrolled and randomized into three groups to receive either
two doses of RIX4414 oral suspension (RIX4414-liq) and
one placebo(Pl) dose, according to a 0,1 month (RIX4414-
RIX4414-Pl group) or a 0,2 month (RIX4414-Pl-RIX4414
group) schedule, or 3 placebo doses(placebo group). Rou-
tine EPI vaccines were administered concomitantly. Serum
anti-rotavirus IgA concentrations (ELISA,cut-off ≥20U/mL)
were determined at pre-Dose1 and 1 month post-Dose2 of
RIX4414-liq. The anti-rotavirus IgA seroconversion(SC) rates
and corresponding Geometric Mean Concentrations(GMCs)
were calculated. Solicited symptoms were collected 8 days
post-each dose, safety data were collected throughout the
study.
Results: At 1 month post-Dose2 of RIX4414-liq, the
anti-rotavirus IgA SC rate was 63.3%(95%CI:54.3;71.6)
in the RIX4414-RIX4414-Pl group(n = 128) and
81.5%(95%CI:73.4;88.0) in the RIX4414-Pl-RIX4414
group(n = 119). The SC rate observed in the placebo group
at the same time points was 7.8%(95%CI:2.6;17.3)(n = 64)
and 15.4%(95%CI:7.6;26.5)(n = 65). Corresponding anti-
rotavirus IgA GMCs for seropositive infants were
253.8U/mL(95%CI:184.8;348.7) in the RIX4414-RIX4414-Pl
group and 338.0U/mL(95%CI:248.2;460.4) in the RIX4414-
Pl-RIX4414 group. There was no evidence of difference
between the RIX4414-liq groups and the placebo group for
serious adverse events, and for reported solicited events.
Conclusion: This study demonstrates that two doses of
RIX4414 (RotarixTM) oral suspension(liquid formulation) co-
administered with routine EPI vaccines in two different
schedules elicit a high immunogenicity response in Viet-
namese children. Seroconversion rates in this setting are in
line with seroconversion rates observed in a large phaseIII
Latin-America study where high efﬁcacy (85%) was observed
against severe RVGE.
doi:10.1016/j.ijid.2008.05.366
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Background: RIX4414(Rotarix, a trademark of Glax-
oSmithKline), an oral live attenuated human rotavirus
(RV) vaccine has previously been shown to be highly
effective against RV gastroenteritis(GE). The efﬁcacy
evaluation of RIX4414 administered concomitantly with
